KalVista Pharmaceuticals (KALV) Other Non Operating Income (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Other Non Operating Income data on file, last reported at $1.9 million in Q3 2025.

• For the quarter ending Q3 2025, Other Non Operating Income rose 22.92% year-over-year to $1.9 million; the trailing twelve-month figure through Jul 2025 stood at $8.8 million (down 19.36% YoY), and the FY2025 full-year result was $4.8 million, down 50.73% from the prior year.
• Other Non Operating Income eased to $1.9 million in Q3 2025, from $5.2 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $9.5 million in Q2 2024 to a low of -$1.3 million in Q4 2023.
• A 5-year average of $1.7 million and a median of $1.3 million in 2024 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income jumped 626.94% in 2021 and plunged 309.78% in 2023, its largest moves.
• Tracing KALV's Other Non Operating Income over 5 years: stood at -$280000.0 in 2021, then fell by 13.21% to -$317000.0 in 2022, then sank by 309.78% to -$1.3 million in 2023, then soared by 105.16% to $67000.0 in 2024, then surged by 2773.13% to $1.9 million in 2025.
• Business Quant data shows KALV's Other Non Operating Income at $1.9 million in Q3 2025, $5.2 million in Q2 2025, and $67000.0 in Q4 2024.